SEARCH

SEARCH BY CITATION

References

  • Aarntzen, E.H., Figdor, C.G., Adema, G.J., Punt, C.J., and De Vries, I.J. (2008). Dendritic cell vaccination and immune monitoring. Cancer Immunol. Immunother. 57, 15591568.
  • Adams, S., O’neill, D.W., Nonaka, D. et al. (2008). Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J. Immunol. 181, 776784.
  • Advani, R., Forero-Torres, A., Furman, R.R., Rosenblatt, J.D., Younes, A., Ren, H., Harrop, K., Whiting, N., and Drachman, J.G. (2009). Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin’s lymphoma. J. Clin. Oncol. 27, 43714377.
  • Ahmadzadeh, M., Felipe-Silva, A., Heemskerk, B., Powell Jr, D.J., Wunderlich, J.R., Merino, M.J., and Rosenberg, S.A. (2008). FOXP3 expression accurately defines the population of intratumoural regulatory T cells that selectively accumulate in metastatic melanoma lesions. Blood 112, 49534960.
  • Ahmadzadeh, M., Johnson, L.A., Heemskerk, B., Wunderlich, J.R., Dudley, M.E., White, D.E., and Rosenberg, S.A. (2009). Tumour antigen-specific CD8 T cells infiltrating the tumour express high levels of PD-1 and are functionally impaired. Blood 114, 15371544.
  • Alexander-Miller, M.A., Leggatt, G.R., and Berzofsky, J.A. (1996). Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl Acad. Sci. USA 93, 41024107.
  • Al-Hajj, M., Wicha, M.S., Benito-Hernandez, A., Morrison, S.J., and Clarke, M.F. (2003). Prospective identification of tumourigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100, 39833988.
  • Allavena, P., Sica, A., Garlanda, C., and Mantovani, A. (2008). The Yin-Yang of tumour-associated macrophages in neoplastic progression and immune surveillance. Immunol. Rev. 222, 155161.
  • Almeida, J.R., Price, D.A., Papagno, L. et al. (2007). Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J. Exp. Med. 204, 24732485.
  • Appay, V., Jandus, C., Voelter, V. et al. (2006). New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumour site. J. Immunol. 177, 16701678.
  • Appay, V., Douek, D.C., and Price, D.A. (2008). CD8+ T cell efficacy in vaccination and disease. Nat. Med. 14, 623628.
  • Attia, P., Phan, G.Q., Maker, A.V. et al. (2005). Autoimmunity correlates with tumour regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 23, 60436053.
  • Banchereau, J., Ueno, H., Dhodapkar, M., Connolly, J., Finholt, J.P., Klechevsky, E., Blanck, J.P., Johnston, D.A., Palucka, A.K., and Fay, J. (2005). Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon. J. Immunother. 28, 505516.
  • Baumgaertner, P., Rufer, N., Devevre, E., Derre, L., Rimoldi, D., Geldhof, C., Voelter, V., Lienard, D., Romero, P., and Speiser, D.E. (2006). Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens. Cancer Res. 66, 19121916.
  • Bendle, G.M., Haanen, J.B., and Schumacher, T.N. (2009). Preclinical development of T cell receptor gene therapy. Curr. Opin. Immunol. 21, 209214.
  • Bennett, M.S., Ng, H.L., Dagarag, M., Ali, A., and Yang, O.O. (2007). Epitope-dependent avidity thresholds for cytotoxic T-lymphocyte clearance of virus-infected cells. J. Virol. 81, 49734980.
  • Bercovici, N., Haicheur, N., Massicard, S. et al. (2008). Analysis and characterization of antitumour T-cell response after administration of dendritic cells loaded with allogeneic tumour lysate to metastatic melanoma patients. J. Immunother. 31, 101112.
  • Berger, C., Jensen, M.C., Lansdorp, P.M., Gough, M., Elliott, C., and Riddell, S.R. (2008). Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J. Clin. Invest. 118, 294305.
  • Betts, M.R., Nason, M.C., West, S.M. et al. (2006). HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107, 47814789.
  • Brandmaier, A.G., Leitner, W.W., Ha, S.P., Sidney, J., Restifo, N.P., and Touloukian, C.E. (2009). High-avidity autoreactive CD4+ T cells induce host CTL, overcome T(regs) and mediate tumour destruction. J. Immunother. 32, 677688.
  • Brichard, V.G., and Lejeune, D. (2008). Cancer immunotherapy targeting tumour-specific antigens: towards a new therapy for minimal residual disease. Expert Opin. Biol. Ther. 8, 951968.
  • Brody, J.R., Costantino, C.L., Berger, A.C., Sato, T., Lisanti, M.P., Yeo, C.J., Emmons, R.V., and Witkiewicz, A.K. (2009). Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival. Cell Cycle 8, 19301934.
  • Bronte, V., and Zanovello, P. (2005). Regulation of immune responses by L-arginine metabolism. Nat. Rev. Immunol. 5, 641654.
  • Cabrera, T., Lara, E., Romero, J.M., Maleno, I., Real, L.M., Ruiz-Cabello, F., Valero, P., Camacho, F.M., and Garrido, F. (2007). HLA class I expression in metastatic melanoma correlates with tumour development during autologous vaccination. Cancer Immunol. Immunother. 56, 709717.
  • Carrasco, J., Van Pel, A., Neyns, B. et al. (2008). Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumour cells. J. Immunol. 180, 35853593.
  • Cassaday, R.D., Sondel, P.M., King, D.M. et al. (2007). A phase I study of immunization using particle-mediated epidermal delivery of genes for gp100 and GM-CSF into uninvolved skin of melanoma patients. Clin. Cancer Res. 13, 540549.
  • Chianese-Bullock, K.A., Pressley, J., Garbee, C. et al. (2005). MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma. J. Immunol. 174, 30803086.
  • Chiong, B., Wong, R., Lee, P., Delto, J., Scotland, R., Lau, R., and Weber, J. (2004). Characterization of long-term effector-memory T-cell responses in patients with resected high-risk melanoma receiving a melanoma Peptide vaccine. J. Immunother. 27, 368379.
  • Collins, A.T., Berry, P.A., Hyde, C., Stower, M.J., and Maitland, N.J. (2005). Prospective identification of tumourigenic prostate cancer stem cells. Cancer Res. 65, 1094610951.
  • Connerotte, T., Van Pel, A., Godelaine, D., Tartour, E., Schuler-Thurner, B., Lucas, S., Thielemans, K., Schuler, G., and Coulie, P.G. (2008). Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities. Cancer Res. 68, 39313940.
  • Daucher, M., Price, D.A., Brenchley, J.M. et al. (2008). Virological outcome after structured interruption of antiretroviral therapy for human immunodeficiency virus infection is associated with the functional profile of virus-specific CD8+ T cells. J. Virol. 82, 41024114.
  • Davis, I.D., Chen, W., Jackson, H. et al. (2004). Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc. Natl Acad. Sci. USA 101, 1069710702.
  • Davis, I.D., Chen, Q., Morris, L. et al. (2006). Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients. J. Immunother. 29, 499511.
  • Davis, I.D., Brady, B., Kefford, R.F. et al. (2009). Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial. Clin. Cancer Res. 15, 21232129.
  • Demotte, N., Stroobant, V., Courtoy, P.J. et al. (2008). Restoring the association of the T cell receptor with CD8 reverses anergy in human tumour-infiltrating lymphocytes. Immunity 28, 414424.
  • Depontieu, F.R., Qian, J., Zarling, A.L. et al. (2009). Identification of tumour-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy. Proc. Natl Acad. Sci. USA 106, 1207312078.
  • Derby, M., Alexander-Miller, M., Tse, R., and Berzofsky, J. (2001). High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL. J. Immunol. 166, 16901697.
  • Dudley, M.E., Wunderlich, J.R., Yang, J.C. et al. (2005). Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23, 23462357.
  • Dudley, M.E., Yang, J.C., Sherry, R. et al. (2008). Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26, 52335239.
  • Ebert, L.M., Liu, Y.C., Clements, C.S. et al. (2009). A long, naturally presented immunodominant epitope from NY-ESO-1 tumour antigen: implications for cancer vaccine design. Cancer Res. 69, 10461054.
  • Ekmekcioglu, S., Ellerhorst, J.A., Prieto, V.G., Johnson, M.M., Broemeling, L.D., and Grimm, E.A. (2006). Tumour iNOS predicts poor survival for stage III melanoma patients. Int. J. Cancer 119, 861866.
  • Fang, D., Nguyen, T.K., Leishear, K., Finko, R., Kulp, A.N., Hotz, S., Van Belle, P.A., Xu, X., Elder, D.E., and Herlyn, M. (2005). A tumourigenic subpopulation with stem cell properties in melanomas. Cancer Res. 65, 93289337.
  • Fay, J.W., Palucka, A.K., Paczesny, S., Dhodapkar, M., Johnston, D.A., Burkeholder, S., Ueno, H., and Banchereau, J. (2006). Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells. Cancer Immunol. Immunother. 55, 12091218.
  • Fontana, R., Bregni, M., Cipponi, A. et al. (2009). Peripheral blood lymphocytes genetically modified to express the self/tumour antigen MAGE-A3 induce antitumour immune responses in cancer patients. Blood 113, 16511660.
  • Fourcade, J., Kudela, P., Andrade Filho, P.A. et al. (2008). Immunization with analog peptide in combination with CpG and montanide expands tumour antigen-specific CD8+ T cells in melanoma patients. J. Immunother. 31, 781791.
  • Fourcade, J., Kudela, P., Sun, Z. et al. (2009). PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J. Immunol. 182, 52405249.
  • Francois, V., Ottaviani, S., Renkvist, N. et al. (2009). The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells. Cancer Res. 69, 43354345.
  • Frank, N.Y., Margaryan, A., Huang, Y., Schatton, T., Waaga-Gasser, A.M., Gasser, M., Sayegh, M.H., Sadee, W., and Frank, M.H. (2005). ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res. 65, 43204333.
  • Gabrilovich, D.I., and Nagaraj, S. (2009). Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9, 162174.
  • Galli, R., Binda, E., Orfanelli, U., Cipelletti, B., Gritti, A., De Vitis, S., Fiocco, R., Foroni, C., Dimeco, F., and Vescovi, A. (2004). Isolation and characterization of tumourigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 64, 70117021.
  • Gallimore, A., Dumrese, T., Hengartner, H., Zinkernagel, R.M., and Rammensee, H.G. (1998). Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. J. Exp. Med. 187, 16471657.
  • Gedye, C., Quirk, J., Browning, J., Svobodova, S., John, T., Sluka, P., Dunbar, P.R., Corbeil, D., Cebon, J., and Davis, I.D. (2009). Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells. Cancer Immunol. Immunother. 58, 16351646.
  • Germeau, C., Ma, W., Schiavetti, F. et al. (2005). High frequency of antitumour T cells in the blood of melanoma patients before and after vaccination with tumour antigens. J. Exp. Med. 201, 241248.
  • Gnjatic, S., Altorki, N.K., Tang, D.N., Tu, S.M., Kundra, V., Ritter, G., Old, L.J., Logothetis, C.J., and Sharma, P. (2009). NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells. Clin. Cancer Res. 15, 21302139.
  • Godet, Y., Moreau-Aubry, A., Guilloux, Y., Vignard, V., Khammari, A., Dreno, B., Jotereau, F., and Labarriere, N. (2008). MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency. J. Exp. Med. 205, 26732682.
  • Gray, J.C., French, R.R., James, S., Al-Shamkhani, A., Johnson, P.W., and Glennie, M.J. (2008). Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies. Eur. J. Immunol. 38, 24992511.
  • Grichnik, J.M., Burch, J.A., Schulteis, R.D., Shan, S., Liu, J., Darrow, T.L., Vervaert, C.E., and Seigler, H.F. (2006). Melanoma, a tumour based on a mutant stem cell? J. Invest. Dermatol. 126, 142153.
  • Hadnagy, A., Gaboury, L., Beaulieu, R., and Balicki, D. (2006). SP analysis may be used to identify cancer stem cell populations. Exp. Cell Res. 312, 37013710.
  • Hamid, O., Solomon, J.C., Scotland, R., Garcia, M., Sian, S., Ye, W., Groshen, S.L., and Weber, J.S. (2007). Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease. Clin. Cancer Res. 13, 215222.
  • Hamzah, J., Jugold, M., Kiessling, F. et al. (2008). Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 453, 410414.
  • Hanada, K., Yewdell, J.W., and Yang, J.C. (2004). Immune recognition of a human renal cancer antigen through post-translational protein splicing. Nature 427, 252256.
  • Harlin, H., Kuna, T.V., Peterson, A.C., Meng, Y., and Gajewski, T.F. (2006). Tumour progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites. Cancer Immunol. Immunother. 55, 11851197.
  • Harlin, H., Meng, Y., Peterson, A.C., Zha, Y., Tretiakova, M., Slingluff, C., Mckee, M., and Gajewski, T.F. (2009). Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res. 69, 30773085.
  • Heemskerk, M.H., Hagedoorn, R.S., Van Der Hoorn, M.A., Van Der Veken, L.T., Hoogeboom, M., Kester, M.G., Willemze, R., and Falkenburg, J.H. (2007). Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. Blood 109, 235243.
  • Heemskerk, B., Liu, K., Dudley, M.E. et al. (2008). Adoptive cell therapy for patients with melanoma, using tumour-infiltrating lymphocytes genetically engineered to secrete interleukin-2. Hum. Gene Ther. 19, 496510.
  • Hermann, P.C., Huber, S.L., Herrler, T., Aicher, A., Ellwart, J.W., Guba, M., Bruns, C.J., and Heeschen, C. (2007). Distinct populations of cancer stem cells determine tumour growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1, 313323.
  • Hersey, P., Menzies, S.W., Coventry, B., Nguyen, T., Farrelly, M., Collins, S., Hirst, D., and Johnson, H. (2005). Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma. Cancer Immunol. Immunother. 54, 208218.
  • Hodi, F.S., Butler, M., Oble, D.A. et al. (2008). Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc. Natl Acad. Sci. USA 105, 30053010.
  • Hunder, N.N., Wallen, H., Cao, J., Hendricks, D.W., Reilly, J.Z., Rodmyre, R., Jungbluth, A., Gnjatic, S., Thompson, J.A., and Yee, C. (2008). Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N. Engl. J. Med. 358, 26982703.
  • Ilkovitch, D., and Lopez, D.M. (2008). Immune modulation by melanoma-derived factors. Exp. Dermatol. 17, 977985.
  • Jager, E., Karbach, J., Gnjatic, S. et al. (2006). Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc. Natl Acad. Sci. USA 103, 1445314458.
  • Jandus, C., Bioley, G., Speiser, D.E., and Romero, P. (2008). Selective accumulation of differentiated FOXP3(+) CD4 (+) T cells in metastatic tumour lesions from melanoma patients compared to peripheral blood. Cancer Immunol. Immunother. 57, 17951805.
  • Jandus, C., Bioley, G., Dojcinovic, D. et al. (2009). Tumour antigen specific FOXP3+ CD4-T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts. Cancer Res. doi: DOI: 10.1158/0008-5472.CAN-09-2226.
  • Johansson, C.C., Egyhazi, S., Masucci, G. et al. (2009). Prognostic significance of tumour iNOS and COX-2 in stage III malignant cutaneous melanoma. Cancer Immunol. Immunother. 58, 10851094.
  • Jorritsma, A., Gomez-Eerland, R., Dokter, M. et al. (2007). Selecting highly affine and well-expressed TCRs for gene therapy of melanoma. Blood 110, 35643572.
  • Kageshita, T., Ishihara, T., Campoli, M., and Ferrone, S. (2005). Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions. Tissue Antigens 65, 419428.
  • Kandalaft, L.E., Facciabene, A., Buckanovich, R.J., and Coukos, G. (2009). Endothelin B receptor, a new target in cancer immune therapy. Clin. Cancer Res. 15, 45214528.
  • Khammari, A., Labarriere, N., Vignard, V. et al. (2009). Treatment of metastatic melanoma with autologous Melan-A/Mart-1-specific cytotoxic T lymphocyte clones. J. Invest. Dermatol. doi: DOI: 10.1038/jid.2009.144.
  • Kim, Y.H., Choi, B.K., Kim, K.H., Kang, S.W., and Kwon, B.S. (2008). Combination therapy with cisplatin and anti-4-1BB: synergistic anticancer effects and amelioration of cisplatin-induced nephrotoxicity. Cancer Res. 68, 72647269.
  • Kim-Schulze, S., Kim, H.S., Fan, Q., Kim, D.W., and Kaufman, H.L. (2009). Local IL-21 promotes the therapeutic activity of effector T cells by decreasing regulatory T cells within the tumour microenvironment. Mol. Ther. 17, 380388.
  • Klebanoff, C.A., Gattinoni, L., and Restifo, N.P. (2006). CD8+ T-cell memory in tumour immunology and immunotherapy. Immunol. Rev. 211, 214224.
  • Klein, W.M., Wu, B.P., Zhao, S., Wu, H., Klein-Szanto, A.J., and Tahan, S.R. (2007). Increased expression of stem cell markers in malignant melanoma. Mod. Pathol. 20, 102107.
  • Klein, O., Ebert, L.M., Nicholaou, T. et al. (2009). Melan-A-specific cytotoxic T cells are associated with tumour regression and autoimmunity following treatment with anti-CTLA-4. Clin. Cancer Res. 15, 25072513.
  • Ko, J.S., Zea, A.H., Rini, B.I. et al. (2009). Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin. Cancer Res. 15, 21482157.
  • Kochenderfer, J.N., and Gress, R.E. (2007). A comparison and critical analysis of preclinical anticancer vaccination strategies. Exp. Biol. Med. (Maywood) 232, 11301141.
  • Kong, L.Y., Wei, J., Sharma, A.K. et al. (2009). A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells. Cancer Immunol. Immunother. 58, 10231032.
  • Kruit, W.H., Van Ojik, H.H., Brichard, V.G. et al. (2005). Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int. J. Cancer 117, 596604.
  • Kruit, W.H., Suciu, S., Dreno, B., Chiarion-Sileni, V., Mortier, L., Robert, C., Maio, M., Brichard, V.G., Lehmann, F., and Keilholz, U. (2008). Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma. J. Clin. Oncol. 26, (May 20 suppl), 2008 ASCO Annual Meeting, abstract 9065.
  • Kryczek, I., Liu, R., Wang, G. et al. (2009). FOXP3 defines regulatory T cells in human tumour and autoimmune disease. Cancer Res. 69, 39954000.
  • Kuball, J., Hauptrock, B., Malina, V., Antunes, E., Voss, R.H., Wolfl, M., Strong, R., Theobald, M., and Greenberg, P.D. (2009). Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain. J. Exp. Med. 206, 463475.
  • Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., Minden, M., Paterson, B., Caligiuri, M.A., and Dick, J.E. (1994). A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645648.
  • Li, B., Vanroey, M., Triebel, F., and Jooss, K. (2008). Lymphocyte activation gene-3 fusion protein increases the potency of a granulocyte macrophage colony-stimulating factor-secreting tumour cell immunotherapy. Clin. Cancer Res. 14, 35453554.
  • Li, B., Vanroey, M., Wang, C., Chen, T.H., Korman, A., and Jooss, K. (2009). Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumour cell immunotherapy providing therapeutic benefit to mice with established tumours. Clin. Cancer Res. 15, 16231634.
  • Liakou, C.I., Kamat, A., Tang, D.N., Chen, H., Sun, J., Troncoso, P., Logothetis, C., and Sharma, P. (2008). CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc. Natl Acad. Sci. USA 105, 1498714992.
  • Lichterfeld, M., Yu, X.G., Mui, S.K. et al. (2007). Selective depletion of high-avidity human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T cells after early HIV-1 infection. J. Virol. 81, 41994214.
  • Lienard, D., Rimoldi, D., Marchand, M. et al. (2004). Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immunol. 4, 4.
  • Linette, G.P., Zhang, D., Hodi, F.S. et al. (2005). Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity. Clin. Cancer Res. 11, 76927699.
  • Loeffler, M., Le’negrate, G., Krajewska, M., and Reed, J.C. (2009). Salmonella typhimurium engineered to produce CCL21 inhibit tumour growth. Cancer Immunol. Immunother. 58, 769775.
  • Lonchay, C., Van Der Bruggen, P., Connerotte, T. et al. (2004). Correlation between tumour regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc. Natl Acad. Sci. USA 101(Suppl 2), 1463114638.
  • Low, L., Mander, A., Mccann, K.J., Dearnaley, D., Tjelle, T.E., Mathiesen, I., Stevenson, F.K., and Ottensmeier, C.H. (2009). DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. Hum. Gene Ther. doi: DOI: 10.1089/hum.2009.067.
  • Lu, S. (2009). Heterologous prime-boost vaccination. Curr. Opin. Immunol. 21, 346351.
  • Lurquin, C., Lethe, B., De Plaen, E., Corbiere, V., Theate, I., Van Baren, N., Coulie, P.G., and Boon, T. (2005). Contrasting frequencies of antitumour and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumour antigen. J. Exp. Med. 201, 249257.
  • Mandruzzato, S., Solito, S., Falisi, E. et al. (2009). IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J. Immunol. 182, 65626568.
  • Markovic, S.N., Suman, V.J., Ingle, J.N. et al. (2006). Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization. Am. J. Clin. Oncol. 29, 352360.
  • Melief, C.J., and Van Der Burg, S.H. (2008). Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat. Rev. Cancer 8, 351360.
  • Messaoudi, I., Guevara Patino, J.A., Dyall, R., Lemaoult, J., and Nikolich-Zugich, J. (2002). Direct link between mhc polymorphism, T cell avidity, and diversity in immune defense. Science 298, 17971800.
  • Meyer, V.S., Drews, O., Gunder, M., Hennenlotter, J., Rammensee, H.G., and Stevanovic, S. (2009). Identification of natural MHC Class II presented phosphopeptides and tumour-derived MHC Class I phospholigands. J. Proteome Res. 8, 36663674.
  • Monzani, E., Facchetti, F., Galmozzi, E. et al. (2007). Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur. J. Cancer 43, 935946.
  • Moon, J.J., Chu, H.H., Pepper, M., Mcsorley, S.J., Jameson, S.C., Kedl, R.M., and Jenkins, M.K. (2007). Naive CD4(+) T cell frequency varies for different epitopes and predicts repertoire diversity and response magnitude. Immunity 27, 203213.
  • Morgan, R.A., Dudley, M.E., Wunderlich, J.R. et al. (2006). Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126129.
  • Morse, M.A., Hobeika, A.C., Osada, T., Serra, D., Niedzwiecki, D., Lyerly, H.K., and Clay, T.M. (2008). Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 112, 610618.
  • Mortarini, R., Piris, A., Maurichi, A. et al. (2003). Lack of terminally differentiated tumour-specific CD8+ T cells at tumour site in spite of antitumour immunity to self-antigens in human metastatic melanoma. Cancer Res. 63, 25352545.
  • Mueller, K., Schweier, O., and Pircher, H. (2008). Efficacy of IL-2- versus IL-15-stimulated CD8 T cells in adoptive immunotherapy. Eur. J. Immunol. 38, 28742885.
  • Nicholaou, T., Ebert, L.M., Davis, I.D. et al. (2009). Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clin. Cancer Res. 15, 21662173.
  • Nistico, P., Capone, I., Palermo, B. et al. (2009). Chemotherapy enhances vaccine-induced antitumour immunity in melanoma patients. Int. J. Cancer 124, 130139.
  • O’Brien, C.A., Pollett, A., Gallinger, S., and Dick, J.E. (2007). A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445, 106110.
  • Obar, J.J., Khanna, K.M., and Lefrancois, L. (2008). Endogenous naive CD8+ T cell precursor frequency regulates primary and memory responses to infection. Immunity 28, 859869.
  • Palucka, A.K., Ueno, H., Connolly, J., Kerneis-Norvell, F., Blanck, J.P., Johnston, D.A., Fay, J., and Banchereau, J. (2006). Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J. Immunother. 29, 545557.
  • Pardoll, D. (2003). Does the immune system see tumours as foreign or self? Annu. Rev. Immunol. 21, 807839.
  • Parkhurst, M.R., Riley, J.P., Igarashi, T., Li, Y., Robbins, P.F., and Rosenberg, S.A. (2004). Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumours endogenously expressing telomerase. Clin. Cancer Res. 10, 46884698.
  • Pilla, L., Patuzzo, R., Rivoltini, L. et al. (2006). A phase II trial of vaccination with autologous, tumour-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients. Cancer Immunol. Immunother. 55, 958968.
  • Powell Jr, D.J., and Rosenberg, S.A. (2004). Phenotypic and functional maturation of tumour antigen-reactive CD8+ T lymphocytes in patients undergoing multiple course peptide vaccination. J. Immunother. 27, 3647.
  • Powell Jr, D.J., Attia, P., Ghetie, V., Schindler, J., Vitetta, E.S., and Rosenberg, S.A. (2008). Partial reduction of human FOXP3+ CD4 T cells in vivo after CD25-directed recombinant immunotoxin administration. J. Immunother. 31, 189198.
  • Rehr, M., Cahenzli, J., Haas, A., Price, D.A., Gostick, E., Huber, M., Karrer, U., and Oxenius, A. (2008). Emergence of polyfunctional CD8+ T cells after prolonged suppression of human immunodeficiency virus replication by antiretroviral therapy. J. Virol. 82, 33913404.
  • Rizzuto, G.A., Merghoub, T., Hirschhorn-Cymerman, D. et al. (2009). Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumour immune response. J. Exp. Med. 206, 849866.
  • Roberts, J.D., Niedzwiecki, D., Carson, W.E. et al. (2006). Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901. J. Immunother. 29, 95101.
  • Rosenberg, S.A., Sherry, R.M., Morton, K.E. et al. (2005). Tumour progression can occur despite the induction of very high levels of self/tumour antigen-specific CD8+ T cells in patients with melanoma. J. Immunol. 175, 61696176.
  • Rubinstein, N., Alvarez, M., Zwirner, N.W., Toscano, M.A., Ilarregui, J.M., Bravo, A., Mordoh, J., Fainboim, L., Podhajcer, O.L., and Rabinovich, G.A. (2004). Targeted inhibition of galectin-1 gene expression in tumour cells results in heightened T cell-mediated rejection; a potential mechanism of tumour-immune privilege. Cancer Cell 5, 241251.
  • Sadelain, M., Brentjens, R., and Riviere, I. (2009). The promise and potential pitfalls of chimeric antigen receptors. Curr. Opin. Immunol. 21, 215223.
  • Saenger, Y.M., and Wolchok, J.D. (2008). The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases. Cancer Immunol. 8, 1.
  • Salcedo, M., Bercovici, N., Taylor, R. et al. (2006). Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumour cell lysate. Cancer Immunol. Immunother. 55, 819829.
  • Schadendorf, D., Ugurel, S., Schuler-Thurner, B. et al. (2006). Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann. Oncol. 17, 563570.
  • Schatton, T., Murphy, G.F., Frank, N.Y. et al. (2008). Identification of cells initiating human melanomas. Nature 451, 345349.
  • Schultz, E.S., Schuler-Thurner, B., Stroobant, V., Jenne, L., Berger, T.G., Thielemanns, K., Van Der Bruggen, P., and Schuler, G. (2004). Functional analysis of tumour-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy. J. Immunol. 172, 13041310.
  • Schwartzentruber, D.J., Lawson, D., Richards, J., Conry, R.M., Miller, D., Triesman, J., Gailani, F., Riley, L.B., Vena., D., and Hwu, P. (2009). A phase III multi-institutional randomized study of immunization with the gp100:209–217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma. J. Clin. Oncol. 27, (18s suppl), 2009 ASCO Annual Meeting, abstract CRA9011.
  • Seder, R.A., Darrah, P.A., and Roederer, M. (2008). T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 8, 247258.
  • Sedlik, C., Dadaglio, G., Saron, M.F., Deriaud, E., Rojas, M., Casal, S.I., and Leclerc, C. (2000). In vivo induction of a high-avidity, high-frequency cytotoxic T-lymphocyte response is associated with antiviral protective immunity. J. Virol. 74, 57695775.
  • Shackleton, M., Davis, I.D., Hopkins, W. et al. (2004). The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immunol. 4, 9.
  • Shen, X., Zhou, J., Hathcock, K.S., Robbins, P., Powell Jr, D.J., Rosenberg, S.A., and Hodes, R.J. (2007). Persistence of tumour infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length. J. Immunother. 30, 123129.
  • Shinozaki, Y., Wang, S., Miyazaki, Y., Miyazaki, K., Yamada, H., Yoshikai, Y., Hara, H., and Yoshida, H. (2009). Tumour-specific cytotoxic T cell generation and dendritic cell function are differentially regulated by interleukin 27 during development of anti-tumour immunity. Int. J. Cancer 124, 13721378.
  • Sikora, A.G., Jaffarzad, N., Hailemichael, Y. et al. (2009). IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumour activity. J. Immunol. 182, 73987407.
  • Singh, S.K., Hawkins, C., Clarke, I.D., Squire, J.A., Bayani, J., Hide, T., Henkelman, R.M., Cusimano, M.D., and Dirks, P.B. (2004). Identification of human brain tumour initiating cells. Nature 432, 396401.
  • Slingluff Jr, C.L., Petroni, G.R., Yamshchikov, G.V. et al. (2004). Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J. Clin. Oncol. 22, 44744485.
  • Slingluff Jr, C.L., Petroni, G.R., Chianese-Bullock, K.A. et al. (2007). Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin. Cancer Res. 13, 63866395.
  • Slingluff Jr, C.L., Petroni, G.R., Olson, W. et al. (2008). Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens. J. Clin. Oncol. 26, 49734980.
  • Smith, C.L., Dunbar, P.R., Mirza, F. et al. (2005a). Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumour antigen epitope in melanoma patients with a high risk of disease recurrence. Int. J. Cancer 113, 259266.
  • Smith, C.L., Mirza, F., Pasquetto, V., Tscharke, D.C., Palmowski, M.J., Dunbar, P.R., Sette, A., Harris, A.L., and Cerundolo, V. (2005b). Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara. J. Immunol. 175, 84318437.
  • Sosman, J.A., Carrillo, C., Urba, W.J. et al. (2008). Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J. Clin. Oncol. 26, 22922298.
  • Spaner, D.E., Astsaturov, I., Vogel, T., Petrella, T., Elias, I., Burdett-Radoux, S., Verma, S., Iscoe, N., Hamilton, P., and Berinstein, N.L. (2006). Enhanced viral and tumour immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100. Cancer 106, 890899.
  • Speiser, D.E., Kyburz, D., Stubi, U., Hengartner, H., and Zinkernagel, R.M. (1992). Discrepancy between in vitro measurable and in vivo virus neutralizing cytotoxic T cell reactivities. Low T cell receptor specificity and avidity sufficient for in vitro proliferation or cytotoxicity to peptide-coated target cells but not for in vivo protection. J. Immunol. 149, 972980.
  • Speiser, D.E., Lienard, D., Rufer, N., Rubio-Godoy, V., Rimoldi, D., Lejeune, F., Krieg, A.M., Cerottini, J.C., and Romero, P. (2005). Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 115, 739746.
  • Speiser, D.E., Baumgaertner, P., Voelter, V., Devevre, E., Barbey, C., Rufer, N., and Romero, P. (2008). Unmodified self antigen triggers human CD8 T cells with stronger tumour reactivity than altered antigen. Proc. Natl Acad. Sci. USA 105, 38493854.
  • Steinman, R.M. (2008). Dendritic cells in vivo: a key target for a new vaccine science. Immunity 29, 319324.
  • Suva, M.L., Riggi, N., Stehle, J.C. et al. (2009). Identification of cancer stem cells in Ewing’s sarcoma. Cancer Res. 69, 17761781.
  • Tacken, P.J., De Vries, I.J., Torensma, R., and Figdor, C.G. (2007). Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat. Rev. Immunol. 7, 790802.
  • Trakatelli, M., Toungouz, M., Blocklet, D. et al. (2006). A new dendritic cell vaccine generated with interleukin-3 and interferon-beta induces CD8+ T cell responses against NA17-A2 tumour peptide in melanoma patients. Cancer Immunol. Immunother. 55, 469474.
  • Tsuji, K., Hamada, T., Uenaka, A. et al. (2008). Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient. Cancer Immunol. Immunother. 57, 14291437.
  • Tuettenberg, A., Becker, C., Huter, E., Knop, J., Enk, A.H., and Jonuleit, H. (2006). Induction of strong and persistent MelanA/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients. Int. J. Cancer 118, 26172627.
  • Uckert, W., and Schumacher, T.N. (2009). TCR transgenes and transgene cassettes for TCR gene therapy: status in 2008. Cancer Immunol. Immunother. 58, 809822.
  • Uenaka, A., Wada, H., Isobe, M. et al. (2007). T cell immunomonitoring and tumour responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein. Cancer Immunol. 7, 9.
  • Ugel, S., Delpozzo, F., Desantis, G., Papalini, F., Simonato, F., Sonda, N., Zilio, S., and Bronte, V. (2009). Therapeutic targeting of myeloid-derived suppressor cells. Curr. Opin. Pharmacol. 9, 470481.
  • Valmori, D., Souleimanian, N.E., Tosello, V. et al. (2007). Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc. Natl Acad. Sci. USA 104, 89478952.
  • Van Baren, N., Bonnet, M.C., Dreno, B. et al. (2005). Tumoural and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J. Clin. Oncol. 23, 90089021.
  • Van Der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van Den Eynde, B., Knuth, A., and Boon, T. (1991). A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254, 16431647.
  • Vigneron, N., Stroobant, V., Chapiro, J., Ooms, A., Degiovanni, G., Morel, S., Van Der Bruggen, P., Boon, T., and Van Den Eynde, B.J. (2004). An antigenic peptide produced by peptide splicing in the proteasome. Science 304, 587590.
  • Viguier, M., Lemaitre, F., Verola, O., Cho, M.S., Gorochov, G., Dubertret, L., Bachelez, H., Kourilsky, P., and Ferradini, L. (2004). Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J. Immunol. 173, 14441453.
  • Voelter, V., Pica, A., Laurent, J., Rimoldi, D., Bouzourene, H., Sajadi, A., Matter, M., Romero, P., Rufer, N., and Speiser, D.E. (2008). An unusual case of metastatic melanoma sensitive to chemotherapy and immunotherapy, with late immune escape in the brain. Cancer Immunol. 8, 6.
  • Von Euw, E.M., Barrio, M.M., Furman, D. et al. (2008). A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10 -1082 promoter genotype as predictor of disease progression. J. Transl. Med. 6, 6.
  • Vonderheide, R.H., Domchek, S.M., Schultze, J.L. et al. (2004). Vaccination of cancer patients against telomerase induces functional antitumour CD8+ T lymphocytes. Clin. Cancer Res. 10, 828839.
  • Vonderheide, R.H., Flaherty, K.T., Khalil, M. et al. (2007). Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J. Clin. Oncol. 25, 876883.
  • Walker, E.B., Haley, D., Miller, W. et al. (2004). gp100(209-2M) peptide immunization of human lymphocyte antigen-A2 +  stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells. Clin. Cancer Res. 10, 668680.
  • Wallen, H., Thompson, J.A., Reilly, J.Z., Rodmyre, R.M., Cao, J., and Yee, C. (2009). Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma. PLoS ONE 4, e4749.
  • Wang, H.Y., Lee, D.A., Peng, G., Guo, Z., Li, Y., Kiniwa, Y., Shevach, E.M., and Wang, R.F. (2004). Tumour-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity 20, 107118.
  • Wang, H.Y., Peng, G., Guo, Z., Shevach, E.M., and Wang, R.F. (2005). Recognition of a new ARTC1 peptide ligand uniquely expressed in tumour cells by antigen-specific CD4+ regulatory T cells. J. Immunol. 174, 26612670.
  • Wang, W., Lau, R., Yu, D., Zhu, W., Korman, A., and Weber, J. (2009). PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+CD25Hi regulatory T cells. Int. Immunol. 21, 10651077.
  • Warren, E.H., Vigneron, N.J., Gavin, M.A. et al. (2006). An antigen produced by splicing of noncontiguous peptides in the reverse order. Science 313, 14441447.
  • Weber, J., Boswell, W., Smith, J. et al. (2008). Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma. J. Immunother. 31, 215223.
  • Weide, B., Carralot, J.P., Reese, A., Scheel, B., Eigentler, T.K., Hoerr, I., Rammensee, H.G., Garbe, C., and Pascolo, S. (2008). Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J. Immunother. 31, 180188.
  • Wherry, E.J., Teichgraber, V., Becker, T.C., Masopust, D., Kaech, S.M., Antia, R., Von Andrian, U.H., and Ahmed, R. (2003). Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat. Immunol. 4, 225234.
  • Wong, R., Lau, R., Chang, J., Kuus-Reichel, T., Brichard, V., Bruck, C., and Weber, J. (2004). Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma. Clin. Cancer Res. 10, 50045013.
  • Yamshchikov, G.V., Mullins, D.W., Chang, C.C. et al. (2005). Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma. J. Immunol. 174, 68636871.
  • Yang, S., Cohen, C.J., Peng, P.D. et al. (2008). Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumour cell recognition. Gene Ther. 15, 14111423.
  • Yee, C., Savage, P.A., Lee, P.P., Davis, M.M., and Greenberg, P.D. (1999). Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J. Immunol. 162, 22272234.
  • Yuan, J., Gnjatic, S., Li, H. et al. (2008). CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc. Natl Acad. Sci. USA 105, 2041020415.
  • Yuan, J., Ku, G.Y., Gallardo, H.F. et al. (2009). Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma. Cancer Immunol. 9, 5.
  • Zeh 3rd H.J., Perry-Lalley, D., Dudley, M.E., Rosenberg, S.A., and Yang, J.C. (1999). High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumour efficacy. J. Immunol. 162, 989994.
  • Zhang, Y., Renkvist, N., Sun, Z., Schuler-Thurner, B., Glaichenhaus, N., Schuler, G., Boon, T., Van Der Bruggen, P., and Colau, D. (2005a). A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells. Eur. J. Immunol. 35, 10661075.
  • Zhang, Y., Sun, Z., Nicolay, H. et al. (2005b). Monitoring of anti-vaccine CD4 T cell frequencies in melanoma patients vaccinated with a MAGE-3 protein. J. Immunol. 174, 24042411.
  • Zhou, J., Shen, X., Huang, J., Hodes, R.J., Rosenberg, S.A., and Robbins, P.F. (2005). Telomere length of transferred lymphocytes correlates with in vivo persistence and tumour regression in melanoma patients receiving cell transfer therapy. J. Immunol. 175, 70467052.
  • Zippelius, A., Batard, P., Rubio-Godoy, V. et al. (2004). Effector function of human tumour-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res. 64, 28652873.
  • Zou, W. (2005). Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5, 263274.